Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation.

Cytokine - 1 Nov 2011

Narimatsu Shogo, Yoshioka Yasuo, Watanabe Hikaru, Masano Takashi, Morishige Tomohiro, Yao Xinglei, Tanabe Aya, Tsunoda Shin-ichi, Tsutsumi Yasuo, Mukai Yohei, Okada Naoki, Nakagawa Shinsaku

Abstract excerpt

The cytokine lymphotoxin-α (LTα) is a promising anticancer agent; however, its instability currently limits its therapeutic potential. Modification of proteins with polyethylene glycol (PEGylation) can improve their in vivo stability, but PEGylation occurs randomly at lysine residues and the N-terminus. Therefore, PEGylated proteins are generally heterogeneous and have lower bioactivity than their non-PEGylated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Electrophoresis, Polyacrylamide Gel

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphotoxin-alpha

Share to Lysine

Share to Mice, Knockout

Share to Mutation

Share to Polyethylene Glycols

Source

Identifiers

PMID: 21871814
DOI: 10.1016/j.cyto.2011.08.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation.PMID 21871814Read ↗

Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.Semantic proximity Read ↗

PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.Semantic proximity Read ↗

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.Semantic proximity Read ↗

Molecular Engineering of Therapeutic CytokinesSemantic proximity Read ↗

Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.Semantic proximity Read ↗

The Art of PEGylation: "From Simple Polymer to Sophisticated Drug Delivery System"Semantic proximity Read ↗

Phage display and PEGylation of therapeutic proteins.Semantic proximity Read ↗

Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).Semantic proximity Read ↗

Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.Semantic proximity Read ↗

Site-directed pegylation of recombinant interleukin-2 at its glycosylation site.Semantic proximity Read ↗

From PEGylation to Next-Generation Polymers: Overcoming Biological Barriers – A ReviewSemantic proximity Read ↗

PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.